News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,485 Results
Type
Article (13944)
Company Profile (101)
Press Release (251440)
Section
Business (88152)
Career Advice (469)
Deals (15372)
Drug Delivery (67)
Drug Development (36720)
Employer Resources (49)
FDA (6304)
Job Trends (6213)
News (150449)
Policy (14067)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (446)
Adcomms (6)
Allergies (32)
Alliances (23248)
ALS (36)
Alzheimer's disease (388)
Antibody-drug conjugate (ADC) (35)
Approvals (6339)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4384)
BIOSECURE Act (9)
Biosimilars (54)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (569)
Cardiovascular disease (67)
Career advice (411)
Career pathing (11)
CAR-T (20)
Cell therapy (81)
Cervical cancer (4)
Clinical research (30919)
Collaboration (319)
Compensation (131)
Complete response letters (16)
COVID-19 (784)
CRISPR (19)
C-suite (112)
Cystic fibrosis (36)
Data (576)
Denatured (15)
Depression (9)
Diabetes (75)
Diagnostics (1320)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32063)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37406)
Executive appointments (347)
FDA (6685)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (204)
Gene editing (37)
Generative AI (8)
Gene therapy (97)
GLP-1 (338)
Government (1300)
Grass and pollen (2)
Guidances (15)
Healthcare (3585)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (34)
Indications (12)
Infectious disease (815)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (60)
IPO (5881)
IRA (29)
Job creations (2054)
Job search strategy (377)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3436)
Liver cancer (19)
Lung cancer (75)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (140)
MASH (30)
Medical device (1280)
Medtech (1283)
Mergers & acquisitions (9676)
Metabolic disorders (243)
Multiple sclerosis (17)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (548)
NextGen: Class of 2025 (1596)
Non-profit (602)
Northern California (663)
Now hiring (7)
Obesity (140)
Opinion (120)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28888)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8044)
Phase II (13080)
Phase III (11759)
Pipeline (377)
Podcasts (46)
Policy (58)
Postmarket research (1405)
Preclinical (3208)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (159)
Real estate (2635)
Recruiting (17)
Regulatory (10094)
Reports (14)
Research institute (569)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (679)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1633)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6733)
Vaccines (158)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (7)
Last 7 days (189)
Last 30 days (899)
Last 365 days (12059)
2025 (2867)
2024 (12513)
2023 (14257)
2022 (19613)
2021 (20159)
2020 (19076)
2019 (14942)
2018 (11755)
2017 (13930)
2016 (13156)
2015 (15486)
2014 (12439)
2013 (10604)
2012 (11402)
2011 (11929)
2010 (10891)
Location
Africa (316)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20097)
Australia (2606)
California (1608)
Canada (864)
China (224)
Colorado (65)
Connecticut (65)
Delaware (51)
Europe (39388)
Florida (299)
Georgia (35)
Idaho (9)
Illinois (180)
India (14)
Indiana (127)
Iowa (1)
Japan (83)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (246)
Massachusetts (1380)
Michigan (27)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (699)
New Mexico (7)
New York (466)
North Carolina (374)
North Dakota (2)
Northern California (663)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (406)
Puerto Rico (8)
Rhode Island (7)
South America (503)
South Carolina (2)
Southern California (679)
Tennessee (34)
Texas (217)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (109)
Wisconsin (14)
265,485 Results for "rocket pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
February 27, 2025
·
11 min read
Policy
FDA Rejects Rocket’s Gene Therapy, Cites Need for Additional CMC Info
Rocket Pharmaceuticals’ gene therapy Kresladi has been hit with an FDA Complete Response Letter requesting additional chemistry, manufacturing and controls information to complete its review.
June 28, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 2, 2025
·
5 min read
Press Releases
Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
December 11, 2024
·
5 min read
Press Releases
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
November 8, 2024
·
5 min read
Press Releases
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference
November 26, 2024
·
5 min read
Policy
Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet needs, today announced a regulatory update for KRESLADI™ (marnetegragene autotemcel; marne-cel), a lentiviral (LV) vector-based gene therapy to treat severe leukocyte adhesion deficiency-I (LAD-I).
June 28, 2024
·
8 min read
Business
Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
May 6, 2024
·
12 min read
Press Releases
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
November 7, 2024
·
11 min read
Pharm Country
Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
Rocket Pharmaceuticals, Inc. today announced that the European Commission (EC), based on a positive opinion issued by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA), has granted orphan medicinal product designation for RP-A601.
May 29, 2024
·
7 min read
1 of 26,549
Next
